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ABSTARCT 
Objective: In this current study analysis is done on the efficiency of the third generation drugs in comparison with tamoxifen, the first line drug 
used in the treatment of breast cancer in postmenopausal patients using computational approach. The drugs are docked with human placental 
aromatase cytochrome P450.  
Methods: The tools and software used are Protein Data Bank, to retrieve the structure of the protein; pubchem compound database, to retrieve the 
chemical structure of the aromatase inhibitors; pharmacophore analysis and the docking analysis using Discovery Studio2.0. 
Results: The results show that all the drugs are more favorable to bind with arginine (Arg) amino acid present in the active site of the protein. 
Letrozole shows good binding affinity with the active site of the protein. 
Conclusion: Among the four drugs, letrozole shows more dock score of 76.566kcal/mol with internal energy of-9.759. On the other hand, tamoxifen 
shows least dock score of 48.494 kcal/mol having internal energy of-4.987. Thus, the docking study reveals that aromatase inhibitors drugs are 
more effective than tamoxifen for treating postmenopausal in women. 
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INTRODUCTION  
An orderly sequence of events leading to the colonization of distal 
organs by malignant cells is often referred to as cancer metastasis 
[1]. Though the devastating consequences of metastasis have been 
recognized, the treatment of cancer is not that effective [2]. Breast 
cancer in 2013 has seen an estimate of 232,340 new cases of 
invasive breast cancer diagnosed among women, as well as an 
estimated 64,640 additional cases of in situ breast cancer. This 
cancer occurs much in women than men, and day by day the patients 
count on breast cancer is increasing rapidly [3]. Breast cancer research 
is going on throughout the world to find the remedy for treating the 
patients; the drug targets has also increased as also an increase in the 
specific pathway to inhibit the progress of cell growth[4]. We have also 
worked on the biological importance of flavonoids and phytochemicals 
[5-7] on HIV [8], diabetics and colon cancer [7]. 
This study is precisely on aromatase inhibitors as these inhibitors 
play a central role in the treatment of breast cancer [9]. Estrogen is 
important and promotes the growth and survival of normal and 
cancer epithelial cells. The chemical compound estrogen binds to the 
estrogen receptor (ER) and the activation of the cell progression 
takes place. The active estrogen receptor tends to bind with 
promoter gene present in the nucleus, which regulates the gene 
activity and translates the protein [4, 9]. The activated receptor in 
turn binds to gene promoters in the nucleus and activates many 
other genes [9, 10]. The activated gene products are thereby 
responsible for cell division, inhibition of cell death, new blood 
vessels formation and protease activity. Rapid expression of 
estrogen receptor is found at earlier stages of breast cancer. Nearly 
70% cancer mainly depends on the over-expression of estrogen 
receptor [11, 12]. 
Aromatase inhibitor inactivates the production of estrogen from 
androgens, by suppressing aromatase enzyme activity. The breast 
cancer patients treated with aromatase inhibitors show, low level of 
estrogen secretion in the tumor cells [13]. The aromatase enzyme is 
responsible for the conversion of androstenedione to estrone and 
testosterone to estradiol, any mutation or overexpression of 
estrogen can be controlled only by inhibiting the conversion process. 
Hence, aromatase is chosen as important drug target protein in 
breast cancer treatment [14, 15]. In this current study, we have tried 
to generate the individual pharmacophore and common feature 
pharmacophore of aromatase inhibitors and tamoxifen. The most 
widely used nonsteroidal antiestrogen in the treatment of breast 
cancer in all its stages is tamoxifen [16]. The main anti-estrogen 
treatments in use consist of third generation aromatase inhibitors, 
such as exemestane, letrozole, and anastrozole [17].  
In the present work, the potential of the aromatase inhibitors 
exemestane, letrozole and anastrozole in the treatment of breast 
cancer has been analyzed using computational approach. The 
pharmacophore features gives an idea about chemical properties 
and biological activity of the drugs. The docking of aromatase 
inhibitors and tamoxifen with human placental aromatase 
cytochrome P450 reveals the role of amino acid, not only at the 
active site but also at the molecular or atomic level interaction of 
these compounds. The secondary structure of the drug target 
protein is shown in fig. 1.  
 
 
Fig. 1: Secondary structure of the target protein 
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MATERIALS AND METHODS 
Retrieval of protein from protein database  
The structure of the drug target protein, the human placental 
aromatase cytochrome P450 and its X-ray crystallographic structure 
with 2.90 Ǻ resolution was retrieved from protein data bank with its 
Identification number as 3EQM, commonly known as PDB ID, is a 
complex with androstenedione. 
Protein preparation  
The raw protein is retrieved from protein data bank and all other 
chemical moieties are present in protein are removed. Energy 
minimization was performed to remove the bad steric clashes with 
1000 steps at RMS gradient of 0.1 and 0.03 respectively. Priorly a 
suitable force field CHARMm, available with Accelrys life science 
software [18] was applied.  
Chemical structure retrieval  
The aromatase inhibitors were obtained after literature analysis and 
its respective chemical structure is retrieved from the PubChem 
compound database (https://pubchem.ncbi.nlm.nih.gov/).  
The list of compounds with their corresponding ID is shown in the 
table 1 and their structure in fig. 2. 
 
Table 1: List of compounds retrieved from pubchem database 
Drugs Pubchem ID SMILES notation 
Anastrozole CID: 2187 CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N 
Exemestane CID: 60198 CC12CCC3C(C1CCC2=O)CC(=C)C4=CC(=O)C=CC34C 
Letrozole CID: 3902 C1=CC(=CC=C1C#N)C(C2=CC=C(C=C2)C#N)N3C=NC=N3 
Tamoxifen CID: 5376 CCC(=C(C1=CC=CC=C1)C2=CC=C(C=C2)OCCN(C)C)C3=CC=CC=C3 
 
 
Fig. 2: The structure aromatase inhibitors drugs 
 
Qualitative pharmacophore analysis 
The individual structure of each compound is retrieved and 
qualitative pharmacophore analysis task was performed by 
optioning best conformation generation with maximum generations 
of 255 conformations per compound. Pharmacophores are aligned 
based on the cat-hip hop algorithm. In this study, we have tried to 
find the individual pharmacophore of each structure.  
Molecular docking  
Structure-based drug design is the method of performing the 
docking using the known protein docking with known ligands. This 
is the frequently used method of analyzing the receptor-ligand 
interaction between the active site of the protein and the chemical 
molecules. In this current study, the PDB ID 3EQM, structure of 
human placental aromatase cytochrome P450 is docked with the 
drugs anastrozole, exemestane, letrozole and tamoxifen. 
RESULTS AND DISCUSSION 
Cavity prediction of protein  
Insilico binding site prediction is one of the important tasks in 
bioinformatics to carry to docking studies. Leis et al., 2010 describes 
that prediction of the accurate binding site on the protein surface 
plays an important role for rational based drug design process with 
relevance to medical applications. He states that many cavities or 
binding site prediction tools are developed rapidly to find the exact 
surface of the protein-binding site [19]. In this study, the binding site 
of the protein is predicted based on erase and flood filling algorithm. 
There are totally 14 sites has been predicted on the by flood filling 
algorithm available in acclerys discovery studio 2.0v software in a 
tool for binding site prediction. Fig. 3 shows the binding site of the 
drug target protein. In the fig. 3: A yellow color shows largest 
binding site whereas other binding sites is shown in green color. Fig. 
3: B shows hydrophobic surface of the protein with yellow color in 
the middle as binding site of the protein.  
 
 
Fig. 3: Binding site of the protein 
 
Chemical feature of the drugs  
The pharmacophore concept describes the chemical and functional 
features of the ligand and its importance for biological processes. 
Dhivya et al., 2012 [20] describes the importance of 
pharmacophore-based screening of natural compounds for colon 
cancer and another study on same year shows the importance of 
plant metabolite axillirain and its pharmacophore analogy virtual 
screening of compounds for HIV based on structure-based drug 
designing study for targeting the drug target protein HIV-1 
protease[7]. The functional group of the each drug plays a vital role 
in biological activity. Replacement or substitution of a functional 
group meant for a specific biological activity, by another functional 
group may increase or decrease the activity of the drug or drug 
candidate.
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Fig. 4: Pharmacophore of the drugs 
 
Fig. 4 shows the individual pharmacophore features of the drugs. 
Commonly green color indicates hydrogen bond acceptor (HBA) and 
cyan color indicates hydrophobic region.4A: shows the six 
pharmacophore feature of the drug anastrozole, among them three 
are HBA and another three features are hydrophobic. In fig. 4B: 
exemestane shows five different features, where three of them are 
hydrophobic and two are acceptors. Similarly, fig. 4C & D shows 
letrozole with five pharmacophore features with three acceptors, 
two hydrophobic, and tamoxifen with four hydrophobic features 
respectively. Whereas, the common features of the four drugs show 
two hydrophobic features and one acceptor.  
This analysis shows that individually each drug has more 
pharmacophore features than the common features generation 
using cat-hip hop. The advantage of common feature generation is to 
fit all the drugs to the aligned pharmacophore of each drug in 
different conformations. In some cases, the drug which do not fit to 
that 3-D spatial arrangement of pharmacophore are neglected from 
the group. Hence is it necessary to generate the individual and 
common feature pharmacophore of drugs or drug candidates. The 
table 2 shows the fit value and different conformation generated for 
aligning common feature pharmacophore generation for the four 
drugs. A fit value reveals the aligning of the compound to common 
pharmacophore feature generated. Among the four drugs 
anastrozole shows more fit value and letrozole shows least fit value.  
 
Table 2: Common feature generation of drugs 
Drugs Fit value Confirmation number 
Anastrozole 3 21 
Tamoxifen 2.70735 67 
Exemestane 2.27961 48 
Letrozole 1.32401 91 
 
Both the drugs and drug target protein is known, and its binding site 
is created automatically using the flood-filling algorithm. It is a 
continuous process of docking the drugs to the different sites of the 
drug target protein until the best ten poses created for drugs to the 
binding site of the protein is over. Ligand fit algorithm is used for 
docking at different sites. Initially the study begins at site 1 to find 
the interaction, least energy value with good dock score is 
considered as efficient docking. In case if, there is no pose or no 
more interaction the study extends for other sites to check the 
possibility of the drug binding to the site. The site 1 with three 
partitions due to large volume 879.125 Ǻ with a point count of 7033 
in equal grid spacing of 0.5 (X),0.5(Y),0.5(Z) direction respectively. 
The drugs were docked with a sphere site being defined as 82.18 (X), 
50.817 (Y),-49.482(Z). Fig. 6 shows the receptor-ligand interaction 
of the drug with the amino acid present at the binding site of drug 
target protein and its dock score, whereas fig. 5 shows the dock 
score and internal energy of the drugs at site 1.  
 
Fig. 5: Docking and internal energy of the drugs 
 
On comparison with tamoxifen, exemestane is effective and well 
tolerated and offers significant early improvement in time to tumor 
progression in the treatment of postmenopausal treatment [21]. 
letrozole, anastrozole and exemestane are third generation 
inhibitors where the former two are non-steroidal and the later one 
steroidal [22]. Lamb,H. M and Adkins,J. C recommends letrozole for 
postmenopausal treatment with advanced breast cancer whose 
disease has progressed on [23]. The results of our analysis also 
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suggests that letrozole, exemestane followed by anastrozole are 
more potent than tamoxifen, in the treatment of breast cancer. 
Regarding side effects, aromatase inhibitors 
 
Fig. 6: Receptor-ligand interaction 
are not found 
associated with enhanced risk of cardiovascular disease, and 
enhanced bone loss is prevented by adding bisphosphonates in 
concert for those at danger of developing osteoporosis [25]. 
Letrozole [23], anastrozole [25] and Exemestane [26], are shown to 




The potential of aromatic inhibitors in the treatment of breast 
cancer has been analysed by computational methods. The present 
study shows that aromatase inhibitors are much more effective than 
tamoxifen in postmenopausal women. Among four drugs, letrozole 
shows more dock score of 76.566kcal/mol with internal energy of-
9.759. On the other hand, tamoxifen shows least dock score of 
48.494 kcal/mol with internal energy of-4.987. Thus, the docking 
study reveals that aromatase inhibitor drugs are more effective than 
tamoxifen for postmenopausal treatment in women. 
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